Clinical significance of serum levels of IGF-1, IGFBP-3, PSA and fPSA in diagnosis of prostate cancer
  
View Full Text  View/Add Comment  Download reader
DOI:10.3724/SP.J.1264.2013.00162
Key words:prostate cancer  insulin-like growth factor-1  insulin-like growth factor binding protein-3
Author NameAffiliationE-mail
MENG Xian-Qin1*, LIU Wei2, DU Wan-Hong1, ZHANG Ying-Jie1, LIU Li-Jun1 (1Department of Geriatrics, Second Affiliated Hospital of Hunan Normal University, Changsha 410003, China
2Department of Medical Affairs, Chinese PLA No.169 Hospital, Hengyang 421000, China) 
mengXianqin1971@163.com 
Hits: 2161
Download times: 2378
Abstract:
      Objective To evaluate the clinical significance of serum levels of insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3) in the diagnosis of prostate cancer (PCa), as well as the significance of their combination with prostate-specific antigen (PSA) and free PSA (fPSA). Methods The serum levels of IGF-1, IGFBP-3, PSA and fPSA were measured with chemoiluminescence immunoassay (CLIA) in 52 patients of pathologically identified prostate cancer, 48 cases of benign prostatic hyperplasia (BPH) and 48 healthy individuals. Results The serum levels of IGF-1 was significantly higher in the PCa group than in the BPH and healthy control groups (P<0.01). However, there was no statistically difference in the IGF-1 level between BPH and healthy control groups (P>0.05). The serum concentration of IGFBP-3 was significantly lower in the PCa group than in the BPH and healthy control groups (P<0.01), and there was also significant difference between BPH and healthy control group (P<0.01). IGF-1 and IGFBP-3 had the sensitivity of 83.6% and 76.4% in the diagnosis of PCa respectively, and specificity of 84.0% and 74.0%, positive prediction value of 85.2% and 76.4%, and negative prediction value of 82.4% and 74.0%, respectively. Combined detection of serum levels of IGF-1 and PSA/fPSA increased the sensitivity of diagnosis significantly. Conclusion Serum levels of IGF-1 and IGFBP-3 are quite different in PCa patients when compared with normal healthy control. Combined application of IGF-1 and PSA or fPSA enhances their clinical value in diagnosis of PCa.
Close